Literature DB >> 7979528

Evaluation of two commercial jet nebulisers and three compressors for the nebulisation of antibiotics.

J C Hung1, G Hambleton, M Super.   

Abstract

Nebulised antibiotics have been shown to be beneficial in the treatment of lung infections in cystic fibrosis. Studies on the efficiency of nebuliser systems are constantly required in view of the large number of compressor/drug/nebuliser combinations which are possible and the development of new systems and drugs. Six combinations of three commercially available compressors were compared (PortaNeb 50 (Medic-Aid; 5.4-6.1 l/min), Turboneb (Medix; 8.3-9.1 l/min), and CR 60 (Medic-Aid; 7.3-7.8 l/min)) and two jet nebulisers (Microneb III (Lifecare) and System 22 Acorn (Medic-Aid)) for the nebulisation of colomycin, gentamicin, and ciprofloxacin. Aerosol droplet size, nebulisation time, and aerosol output were determined. Turboneb and CR 60 reduced the nebulisation time and produced higher proportions of 'respirable' (< 5 microns diameter) antibiotic aerosols. The residual volume of the Microneb III was lower than that of the System 22 Acorn. It was found that the Turboneb and CR 60, when coupled with either Microneb III or System 22 Acorn, were suitable for the nebulisation of all three antibiotics. Of the equipment tested, Turboneb coupled with Microneb III was the most efficient combination. Even with this combination, only around 50% of the nominal dose was released as respirable aerosol.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7979528      PMCID: PMC1030014          DOI: 10.1136/adc.71.4.335

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  13 in total

1.  Why nebulise for more than five minutes?

Authors:  C O'Callaghan; A R Clark; A D Milner
Journal:  Arch Dis Child       Date:  1989-09       Impact factor: 3.791

2.  The flow-pressure characteristics of compressors used for inhalation therapy.

Authors:  S P Newman; P G Pellow; S W Clarke
Journal:  Eur J Respir Dis       Date:  1987-08

Review 3.  Therapeutic aerosols 2--Drugs available by the inhaled route.

Authors:  S W Clarke; S P Newman
Journal:  Thorax       Date:  1984-01       Impact factor: 9.139

4.  Assessment of jet nebulisers for lung aerosol therapy.

Authors:  M M Clay; D Pavia; S P Newman; T Lennard-Jones; S W Clarke
Journal:  Lancet       Date:  1983-09-10       Impact factor: 79.321

5.  Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Authors:  M E Hodson; A R Penketh; J C Batten
Journal:  Lancet       Date:  1981-11-21       Impact factor: 79.321

6.  Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis.

Authors:  J M Littlewood; M G Miller; A T Ghoneim; C H Ramsden
Journal:  Lancet       Date:  1985-04-13       Impact factor: 79.321

Review 7.  Aerosol antibiotic treatment in cystic fibrosis.

Authors:  J M Littlewood; S W Smye; H Cunliffe
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

Review 8.  Therapeutic aerosols 1--physical and practical considerations.

Authors:  S P Newman; S W Clarke
Journal:  Thorax       Date:  1983-12       Impact factor: 9.139

9.  Evaluation of jet nebulisers for use with gentamicin solution.

Authors:  S P Newman; P G Pellow; M M Clay; S W Clarke
Journal:  Thorax       Date:  1985-09       Impact factor: 9.139

10.  Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection.

Authors:  T Jensen; S S Pedersen; S Garne; C Heilmann; N Høiby; C Koch
Journal:  J Antimicrob Chemother       Date:  1987-06       Impact factor: 5.790

View more
  2 in total

1.  Running a domiciliary nebuliser service.

Authors:  R S Wilson; M F Muers
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

2.  Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.

Authors:  Argyris Michalopoulos; Sofia K Kasiakou; Zefi Mastora; Kostas Rellos; Anastasios M Kapaskelis; Matthew E Falagas
Journal:  Crit Care       Date:  2005-01-06       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.